CytomX Therapeutics Inc (NASDAQ: CTMX) started the day on Thursday, with a price decrease of -5.08% at $1.12, before settling in for the price of $1.18 at the close. Taking a more long-term approach, CTMX posted a 52-week range of $0.83-$5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 28.25%. Meanwhile, its Annual Earning per share during the time was 67.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -328.04%. This publicly-traded company’s shares outstanding now amounts to $78.23 million, simultaneously with a float of $76.94 million. The organization now has a market capitalization sitting at $87.65 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0698, while the 200-day Moving Average is $1.5556.
CytomX Therapeutics Inc (CTMX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. CytomX Therapeutics Inc’s current insider ownership accounts for 1.69%, in contrast to 65.49% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’24, this organization’s Chief Business Officer sold 4,181 shares at the rate of 1.23, making the entire transaction reach 5,139 in total value, affecting insider ownership by 119,056. Preceding that transaction, on Aug 20 ’24, Company’s SVP, Chief Scientific Officer sold 4,181 for 1.23, making the whole transaction’s value amount to 5,139. This particular insider is now the holder of 175,648 in total.
CytomX Therapeutics Inc (CTMX) Earnings and Revenue Records
CytomX Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -328.04% and is forecasted to reach -0.43 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -0.90% through the next 5 years, which can be compared against the 67.21% growth it accomplished over the previous five years trading on the market.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Let’s observe the current performance indicators for CytomX Therapeutics Inc (CTMX). It’s Quick Ratio in the last reported quarter now stands at 1.04. The Stock has managed to achieve an average true range (ATR) of 0.10. Alongside those numbers, its PE Ratio stands at $6.60, and its Beta score is 1.03. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.69.
In the same vein, CTMX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.17, a figure that is expected to reach -0.20 in the next quarter, and analysts are predicting that it will be -0.43 at the market close of one year from today.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
If we take a close look at the recent performances of CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days Average volume was 0.94 million that shows plunge from its year to date volume of 2.47 million. During the previous 9 days, stock’s Stochastic %D was recorded 38.57% While, its Average True Range was 0.1058.
Raw Stochastic average of CytomX Therapeutics Inc (CTMX) in the period of the previous 100 days is set at 42.39%, which indicates a major fall in contrast to 46.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 89.68% that was higher than 61.82% volatility it exhibited in the past 100-days period.
